ARCHIVES

With $1.1 Billion At Stake, Cancer Groups Mull Comparative Effectiveness Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 20 | May 22, 2009

Download PDF Visit The Full Archive

Related Articles

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

NCI-Approved Clinical Trials

December 31, 2004

NCI To Sponsor Its Own Predoctoral Training At Some Institutions With Postdoctoral Awards

January 31, 1975

CPRIT Likely to Get Funding For Two Years; DePinho Announces Austerity Measures

May 17, 2013

In Brief: Elizabeth Miller Dies; Mihich Names Associate Director At RPMI; AACR Calls For Abstracts

October 23, 1987

Interferon “Hysteria” Prompts ASCO To Warn Against Expecting Immediate Benefits

June 20, 1980